Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Opsens Inc T.OPS

OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Company’s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR... see more

TSX:OPS - Post Discussion

Opsens Inc > stockwatch.com
View:
Post by Possibleidiot01 on Oct 16, 2023 4:28pm

stockwatch.com

Still looking for a Bloom and Burton comment on deal .


Globe says Opsens accepts $345-million offer

 

2023-10-11 08:29 ET - In the News

 

The Globe and Mail reports in its Wednesday edition that Quebec City heart technology maker Opsens has agreed to sell itself to Boston health care player Haemonetics for $345-million. The Globe's Sean Silcoff writes that it is the biggest acquisition of a Canadian medical device business since Boston Scientific bought Baylis Medical's cardiovascular devices unit for $1.75-billion (U.S.) early last year. Haemonetics has agreed to pay $2.90 a share for Toronto Stock Exchange-listed Opsens, or 50 per cent above its latest closing price. Opsens sells technology it has developed that uses fibre optic sensors and stainless-steel guidewires to assess and treat coronary ailments, including blocked arteries and heart valve issues. The 300-person company generated revenue of $31.6-million in the nine months ended May 31, up 33 per cent year-over-year. Much of its recent momentum has been driven by sales of its Savvywire product, which enables "faster and safer delivery of transcatheter aortic valve replacement, leading to better outcomes and lower cost," said David Martin, an analyst with Bloom Burton in Toronto. Mr. Martin said Opsens had been careful to launch Savvywire with a focus on training and working out early kinks.



Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities